RT Journal Article
SR Electronic
T1 P1 variants and key amino acid mutations at the Spike gene identified using Sanger protocols
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.21.21253158
DO 10.1101/2021.03.21.21253158
A1 Cabral, Gabriela Bastos
A1 Ahagon, Cintia Mayumi
A1 Lopez-Lopes, Giselle Ibette Silva
A1 Hussein, Igor Mohamed
A1 Guimaraes, Paula Morena
A1 Cilli, Audrey
A1 Silva, Valeria Oliveira
A1 Timenetsky, Maria do Carmo CT
A1 de Jesus Alves, Ivy
A1 Bombonatte, Andrea GC
A1 dos Santos, Fabiana C Pereira
A1 Brígido, Luís Fernando de Macedo
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.21.21253158.abstract
AB SARS-CoV-2 variants, along with vaccination, mark the second year of the pandemic. The spike region is a focal point in COVID-19 pathogenesis, with different amino acid changes potentially modulating vaccine response and some being part of variant signatures. NGS is the standard tool to sequence the virus but limitations of different sources hinders expansion of genomic surveillance in many places. To improve surveillance capability we developed a Sanger based sequencing protocol to obtain coverage of most (>95%) spike gene. Eleven nasopharyngeal swabs collections had RNA extracted for real time PCR diagnosis and leftover RNA had up to 3785 bp sequenced at an ABI3500 using dye termination chemistry of nested PCR products of two reactions of one-step RT-PCR. P1 amino acid mutations signatures were present in 18% (2/11), with 82% (9/11) with three or more additional amino acid changes (GISAID CoVsurver list). Most sequences (86%, 6/7) from 2021 have the E484K, whereas the mutation was not present in samples collected in 2020 (0/4, p=0.015).The swiftness that favorable mutations to the virus may prevail and their potential impact in vaccines and other current interventions need broader surveillance and more public health attention.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthis is an exploratory work not a clinical trialFunding StatementStudy developed with institutional fundsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out in accordance with the Declaration of Helsinki as revised in 2000, and approved by the Ethics Committee of the Adolfo Lutz Institute, Sao Paulo, Brazil. The study was registered at the institute, CTC 18M/2020 and CTC 39M/2020 and at the institutional ethical committee - CAAE: 31924420.8.0000.0059 and CAAE: 43250620.4.1001.0059. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence deposite at GISAID, non confidential data not already submitted with sequences available upon request